Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

The LATAM pain management drugs market was valued at $2,683.82 million in 2019, and is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027. The length of pain ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

This estimation was drawn from an analysis of data from consumer advocacy Public Citizen and Imperial College London that had been conducted by the international non-profit Oxfam. Pfizer has not ...

A string of pharmaceutical bosses attended a three-hour dinner at Donald Trump’s Mar-a-Lago resort in Florida in December.

Pfizer and Allergan have confirmed that they ... driven by the potential savings they are able to deliver to healthcare systems. The ISPE Singapore Affiliate Conference & Exhibition is one of ...

Delivering room-temperature air through the nose to cool the sphenopalatine ganglion taps into a powerful neuromodulatory ...